Advertisement
ALXO vs ARVN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALXO is a Hold and ARVN is a Hold.
ALXO's RSI Indicator ascends from oversold territory
The RSI Oscillator for ALXO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 38 of the 44 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALXO just turned positive on October 19, 2026. Looking at past instances where ALXO's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.
Following a +11.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALXO advanced for three days, in 212 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 46 cases where ALXO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALXO as a result. In 76 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALXO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALXO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALXO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ALXO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.173) is normal, around the industry mean (3.498). P/E Ratio (-1.004) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALXO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ARVN sees its Stochastic Oscillator ascending out of oversold territory
On November 11, 2026, the Stochastic Oscillator for ARVN moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 55 instances where the indicator left the oversold zone. In 45 of the 55 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Oscillator exited the oversold zone, 22 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +7.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In 77 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for ARVN turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ARVN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (3.498). P/E Ratio (21.367) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ALXO | ARVN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 36 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 86 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 83 | |
PRICE GROWTH RATING 1..100 | 79 | 75 | |
P/E GROWTH RATING 1..100 | 12 | 71 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARVN's Valuation (86) in the Biotechnology industry is in the same range as ALXO (92) in the null industry. This means that ARVN’s stock grew similarly to ALXO’s over the last 12 months.
ARVN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ALXO (100) in the null industry. This means that ARVN’s stock grew similarly to ALXO’s over the last 12 months.
ARVN's SMR Rating (83) in the Biotechnology industry is in the same range as ALXO (98) in the null industry. This means that ARVN’s stock grew similarly to ALXO’s over the last 12 months.
ARVN's Price Growth Rating (75) in the Biotechnology industry is in the same range as ALXO (79) in the null industry. This means that ARVN’s stock grew similarly to ALXO’s over the last 12 months.
ALXO's P/E Growth Rating (12) in the null industry is somewhat better than the same rating for ARVN (71) in the Biotechnology industry. This means that ALXO’s stock grew somewhat faster than ARVN’s over the last 12 months.
| ALXO | ARVN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 71% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 84% |
| MACD ODDS (%) | 1 day ago 77% | 1 day ago 85% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 83% |
| Advances ODDS (%) | 3 days ago 86% | 2 days ago 80% |
| Declines ODDS (%) | 16 days ago 90% | 6 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 86% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALXO’s FA Score shows that 1 FA rating(s) are green while ARVN’s FA Score has 0 green FA rating(s).
- ALXO’s FA Score: 1 green, 4 red.
- ARVN’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALXO’s TA Score shows that 4 TA indicator(s) are bullish while ARVN’s TA Score has 4 bullish TA indicator(s).
- ALXO’s TA Score: 4 bullish, 4 bearish.
- ARVN’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALXO (@Biotechnology) experienced а -13.95% price change this week, while ARVN (@Biotechnology) price change was -2.40% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ALXO is expected to report earnings on Nov 13, 2026.
ARVN is expected to report earnings on Mar 01, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALXO and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALXO has been loosely correlated with MDGL. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ALXO jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To ALXO | 1D Price Change % | ||
|---|---|---|---|---|
| ALXO | 100% | +0.90% | ||
| MDGL - ALXO | 56% Loosely correlated | +0.10% | ||
| AXON - ALXO | 45% Loosely correlated | +4.26% | ||
| AMRN - ALXO | 43% Loosely correlated | -0.34% | ||
| ARVN - ALXO | 38% Loosely correlated | -0.14% | ||
| FHTX - ALXO | 37% Loosely correlated | +10.00% | ||
More | ||||
ARVN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with OLMA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then OLMA could also see price increases.
| Ticker / NAME | Correlation To ARVN | 1D Price Change % | ||
|---|---|---|---|---|
| ARVN | 100% | -0.14% | ||
| OLMA - ARVN | 48% Loosely correlated | +10.59% | ||
| BCYC - ARVN | 47% Loosely correlated | N/A | ||
| AXON - ARVN | 46% Loosely correlated | +4.26% | ||
| VCYT - ARVN | 46% Loosely correlated | +4.36% | ||
| STOK - ARVN | 46% Loosely correlated | +2.02% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PSTP | 37.43 | 0.26 | +0.69% |
| Innovator Power Buffer Step-Up Strategy ETF (PSTP) | |||
| FLGR | 33.52 | 0.11 | +0.32% |
| Franklin FTSE Germany ETF (FLGR) | |||
| CGSD | 25.36 | -0.03 | -0.12% |
| Capital Group Short Duration Income ETF (CGSD) | |||
| WIP | 37.43 | -0.10 | -0.27% |
| State Street SPDR FTSE International Government Inflation-Protected Bond ETF (WIP) | |||
| REW | 12.50 | -0.87 | -6.51% |
| ProShares UltraShort Technology (REW) | |||